Anteris Technologies GlobalASX:AVR -3.54%50 Cyclically Adjusted PB Ratio is 3.89 as of Jul. 09, 2026, which is 166% above its 10-year median of 1.46. GuruFocus rates ASX:AVR with a GF Score™ of 50/100. The stock has 7 warning signs investors should review. Among 524 Medical Devices & Instruments companies, Anteris Technologies Global ranks worse than 71.76% on this metric.
The historical rank and industry rank for Anteris Technologies Global's Cyclically Adjusted PB Ratio or its related term are showing as below:
ASX:AVR'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.58 Med: 1.46 Max: 3.85
Current: 3.64
During the past years, Anteris Technologies Global's highest Cyclically Adjusted PB Ratio was 3.85. The lowest was 0.58. And the median was 1.46.
ASX:AVR's Cyclically Adjusted PB Ratio is ranked worse than 71.76% of 524
companies
in the Medical Devices & Instruments industry
Industry Median: 1.785
vs ASX:AVR: 3.64
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Anteris Technologies Global's adjusted book value per share data for the three months ended in Mar. 2026 was A$4.081. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is A$3.50 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Anteris Technologies Global (ASX:AVR) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Anteris Technologies Global Cyclically Adjusted PB Ratio Related Terms
Anteris Technologies Global Cyclically Adjusted PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anteris Technologies Global Cyclically Adjusted PB Ratio Chart
ASX:AVR vs QDEL, INMD, CNMD: Cyclically Adjusted PB Ratio Comparison
For the Medical Devices subindustry, Anteris Technologies Global's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anteris Technologies Global Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Anteris Technologies Global's Cyclically Adjusted PB Ratio falls into.
Anteris Technologies Global Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 3.89 mean?
Anteris Technologies Global (ASX:AVR) has a Cyclically Adjusted PB Ratio of 3.89 as of Jul. 09, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Anteris Technologies Global and its competitors. This is 166% above median its historical median of 1.46. Over the past decade, Anteris Technologies Global's Cyclically Adjusted PB Ratio has ranged from 0.58 to 3.85. According to the industry distribution chart, Anteris Technologies Global ranks #376 out of 524 companies in the Medical Devices & Instruments industry, placing it in the top 71.8%.
Is Anteris Technologies Global's Cyclically Adjusted PB Ratio too high?
Anteris Technologies Global's current Cyclically Adjusted PB Ratio of 3.89 is 166% above median its 10-year median of 1.46. Over the past 10 years, this metric has ranged from a low of 0.58 to a high of 3.85. The Medical Devices & Instruments industry median Cyclically Adjusted PB Ratio is 1.79. Anteris Technologies Global's value of 3.89 is 117.9% above this industry median. Based on the distribution chart, Anteris Technologies Global ranks #376 out of 524 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Anteris Technologies Global has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's Cyclically Adjusted PB Ratio compare to QDEL and INMD?
According to the Medical Devices & Instruments industry distribution chart, Anteris Technologies Global ranks #376 out of 524 companies for Cyclically Adjusted PB Ratio. This places Anteris Technologies Global in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.79. Anteris Technologies Global's value of 3.89 is 117.9% above this benchmark. Historically, Anteris Technologies Global's own Cyclically Adjusted PB Ratio has ranged from 0.58 to 3.85 over the past decade. While the company's 10-year median is 1.46 vs. the industry median of 1.79, Anteris Technologies Global has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PB Ratio among Medical Devices & Instruments companies is 1.79, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anteris Technologies Global's current Cyclically Adjusted PB Ratio of 3.89 is 117.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Anteris Technologies Global and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PB Ratio is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anteris Technologies Global's current Cyclically Adjusted PB Ratio is 3.89, which is 166% above median its own 10-year median of 1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (ASX:AVR) has a current Cyclically Adjusted PB Ratio of 3.89. The current Cyclically Adjusted PB Ratio is 3.89, which is 166% above median its 10-year median of 1.46 and 117.9% above the Medical Devices & Instruments industry median of 1.79. Anteris Technologies Global's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Anteris Technologies Global (ASX:AVR), the current Cyclically Adjusted PB Ratio is 3.89 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
50GF Score
Get the complete analysis for ASX:AVR
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVR has been successfully added to your 
